Omnicell (NASDAQ:OMCL) Given New $44.00 Price Target at JPMorgan Chase & Co.

Omnicell (NASDAQ:OMCL) had its price target increased by JPMorgan Chase & Co. from $37.00 to $44.00 in a research note released on Thursday morning,Benzinga reports. The firm currently has a neutral rating on the stock.

Several other analysts have also recently weighed in on OMCL. Barclays raised their target price on shares of Omnicell from $39.00 to $58.00 and gave the company an “equal weight” rating in a report on Thursday, October 31st. Craig Hallum lifted their price target on Omnicell from $45.00 to $64.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. Benchmark reiterated a “buy” rating and issued a $48.00 price target on shares of Omnicell in a research note on Wednesday, October 9th. Bank of America reaffirmed a “neutral” rating and issued a $57.00 target price (up from $44.00) on shares of Omnicell in a research report on Thursday, October 31st. Finally, Wells Fargo & Company upped their price objective on shares of Omnicell from $30.00 to $41.00 and gave the company an “equal weight” rating in a research note on Monday, October 14th. Five investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $52.00.

Omnicell Stock Up 3.6 %

Omnicell stock opened at $45.69 on Thursday. Omnicell has a 52-week low of $25.12 and a 52-week high of $55.74. The firm has a market cap of $2.12 billion, a PE ratio of -117.15, a price-to-earnings-growth ratio of 37.10 and a beta of 0.81. The company’s 50 day moving average is $44.27 and its two-hundred day moving average is $37.41.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. GAMMA Investing LLC raised its holdings in shares of Omnicell by 78.4% in the third quarter. GAMMA Investing LLC now owns 1,258 shares of the company’s stock worth $55,000 after acquiring an additional 553 shares during the last quarter. Nisa Investment Advisors LLC lifted its position in Omnicell by 248.8% during the second quarter. Nisa Investment Advisors LLC now owns 1,402 shares of the company’s stock valued at $38,000 after buying an additional 1,000 shares in the last quarter. 1620 Investment Advisors Inc. raised its position in Omnicell by 230.1% in the third quarter. 1620 Investment Advisors Inc. now owns 2,212 shares of the company’s stock valued at $96,000 after purchasing an additional 1,542 shares during the period. EntryPoint Capital LLC grew its stake in shares of Omnicell by 121.2% in the first quarter. EntryPoint Capital LLC now owns 2,455 shares of the company’s stock valued at $72,000 after buying an additional 1,345 shares in the last quarter. Finally, CWM LLC boosted its holdings in Omnicell by 68.2% in the 2nd quarter. CWM LLC now owns 3,048 shares of the company’s stock worth $83,000 after acquiring an additional 1,236 shares during the period. Institutional investors and hedge funds own 97.70% of the company’s stock.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.